# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...
Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of Opdivo to eval...
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.
- Bloomberg